1-20 of 20
Daniela Matei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer

Yinu Wang, Xiaolei Situ, Horacio Cardenas, Ellie Siu, Sayedabdulrazzaq A. Alhunayan, Russell Keathley, Edward Tanner, Jian-Jun Wei, Yuying Tan, Chinmayee Vallabh Prabhu Dessai, Ji-Xin Cheng, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1175–1188.
https://doi.org/10.1158/1078-0432.CCR-23-2368
Published: 15 March 2024
View article titled, Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Open the PDF for Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A36: Developing a novel treatment for advanced ovarian cancer by targeting the c-Met pathway

Anusha Chaparala, Wendy M. Swetzig, Anna E. Strohl, Jian-Jun Wei, Daniela Matei, Shohreh Shahabi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A36.
https://doi.org/10.1158/1557-3265.OVCA19-A36
Published: 01 July 2020
View article titled, Abstract A36: Developing a novel treatment for advanced ovarian cancer by targeting the c-Met pathway
Journal Articles

Abstract A80: Targeting ovarian cancer stem cell by Dot1L inhibition

Yaqi Zhang, Yinu Wang, Guangyuan Zhao, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A80.
https://doi.org/10.1158/1557-3265.OVCA19-A80
Published: 01 July 2020
View article titled, Abstract A80: Targeting ovarian cancer stem cell by Dot1L inhibition
Journal Articles

Abstract A76: Role of frizzled-7 in platinum tolerance ovarian cancer

Yinu Wang, Guanyuan Zhao, Hao Huang, Salvatore Condello, Jianjun Wei, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A76.
https://doi.org/10.1158/1557-3265.OVCA19-A76
Published: 01 July 2020
View article titled, Abstract A76: Role of frizzled-7 in platinum tolerance ovarian cancer
Journal Articles

Abstract B56: Tissue transglutaminase/Frizzled receptor clusters regulate WNT transcriptional activity in ovarian cancer stem cells

Salvatore Condello, Livia Sima, Cristina Ivan, Horacio Cardenas, Gary Schiltz, Rama Mishra, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): B56.
https://doi.org/10.1158/1557-3265.OVCA19-B56
Published: 01 July 2020
View article titled, Abstract B56: Tissue transglutaminase/Frizzled receptor clusters regulate WNT transcriptional activity in ovarian cancer stem cells
Journal Articles

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean Hurteau, Koji Matsuo, Daniela Matei, Waldo Jimenez, Carolyn Johnston, Mihaela Cristea, Katia Tonkin, Prafull Ghatage, Stephanie Lheureux, Anjali Mehta, Judy Quintos, Qian Tan, Suzanne Kamel-Reid, Olga Ludkovski, Ming-Sound Tsao, John J. Wright, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2477–2486.
https://doi.org/10.1158/1078-0432.CCR-19-2576
Published: 01 June 2020
View article titled, Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Open the PDF for Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A25: Tissue transglutaminase interacts with Frizzled 7 in ovarian cancer stem cells

Salvatore Condello, Livia Sima, Cristina Ivan, Horacio Cardenas, Gary Schiltz, Rama K Mishra, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): A25.
https://doi.org/10.1158/1557-3265.OVCA17-A25
Published: 01 August 2018
View article titled, Abstract A25: Tissue transglutaminase interacts with Frizzled 7 in ovarian cancer stem cells
Journal Articles

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Nicholas Pulliam, Fang Fang, Ali R. Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz V. Rassool, Kathy D. Miller, Kenneth P. Nephew
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (13): 3163–3175.
https://doi.org/10.1158/1078-0432.CCR-18-0204
Published: 01 July 2018
View article titled, An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Open the PDF for An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses

Daniela Matei, Sharad Ghamande, Lynda Roman, Angeles Alvarez Secord, John Nemunaitis, Merry Jennifer Markham, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Xiang Yao Su, Harold Keer, Mohammad Azab, Gini F. Fleming
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2285–2293.
https://doi.org/10.1158/1078-0432.CCR-17-3055
Published: 14 May 2018
View article titled, A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Open the PDF for A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses in another window
Includes: Supplementary data
Journal Articles

Abstract AP21: LIPID DESATURATION IS A METABOLIC MARKER AND THERAPEUTIC TARGET OF OVARIAN CANCER STEM CELLS

Junjie Li, Salvatore Condello, Jessica Thomes-Pepin, Xiaoxiao Ma, Yu Xia, Thomas D. Hurley, Ji-Xin Cheng, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): AP21.
https://doi.org/10.1158/1557-3265.OVCASYMP16-AP21
Published: 31 May 2017
View article titled, Abstract AP21: LIPID DESATURATION IS A METABOLIC MARKER AND THERAPEUTIC TARGET OF OVARIAN CANCER STEM CELLS
Journal Articles

Abstract A70: Epigenome and genome alterations in platinum resistant ovarian tumors.

Fang Fang, Horacio Cardenas, Dave Miller, Aaron Buechlein, Qing Yu, Yunlong Liu, Guanglong Jiang, Pietro Taverna, Harold Keer, Doug Rusch, Daniela Matei, Kenneth P. Nephew
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): A70.
https://doi.org/10.1158/1557-3265.OVCA15-A70
Published: 15 January 2016
View article titled, Abstract A70: Epigenome and genome alterations in platinum resistant ovarian tumors.
Journal Articles

Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression

Jiyoon Lee, Salvatore Condello, Bakhtiyor Yakubov, Robert Emerson, Andrea Caperell-Grant, Kiyotaka Hitomi, Jingwu Xie, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4482–4493.
https://doi.org/10.1158/1078-0432.CCR-15-0226
Published: 30 September 2015
View article titled, Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Open the PDF for Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression in another window
Includes: Supplementary data
Journal Articles

Abstract POSTER-THER-1421: Epigenetic targeting of ovarian cancer stem cells

Yinu Wang, Horacio Cardenas, Fang Fang, Salvatore Condello, Pietro Taverna, Matthew Segar, Yunlong Liu, Daniela Matei, Kenneth P. Nephew
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): POSTER-THER-1421.
https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-THER-1421
Published: 15 August 2015
View article titled, Abstract POSTER-THER-1421: Epigenetic targeting of ovarian cancer stem cells
Journal Articles

Abstract POSTER-BIOL-1309: Beta-catenin regulated ALDH1A1 is a target in ovarian cancer stem cells

Salvatore Condello, Sarbajeet Nagdas, Cynthia Morgan, John Turek, Thomas Hurley, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): POSTER-BIOL-1309.
https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-BIOL-1309
Published: 15 August 2015
View article titled, Abstract POSTER-BIOL-1309: Beta-catenin regulated ALDH1A1 is a target in ovarian cancer stem cells
Journal Articles

Abstract POSTER-BIOL-1306: DNA methylation changes during epithelial-to-mesenchymal transition in ovarian cancer cells

Horacio Cardenas, Edyta Vieth, Jiyoon Lee, Yunlong Liu, Kenneth P. Nephew, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): POSTER-BIOL-1306.
https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-BIOL-1306
Published: 15 August 2015
View article titled, Abstract POSTER-BIOL-1306: DNA methylation changes during epithelial-to-mesenchymal transition in ovarian cancer cells
Journal Articles

The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer

Fang Fang, Joanne Munck, Jessica Tang, Pietro Taverna, Yinu Wang, David F.B. Miller, Jay Pilrose, Gavin Choy, Mohammad Azab, Katherine S. Pawelczak, Pamela VanderVere-Carozza, Michael Wagner, John Lyons, Daniela Matei, John J. Turchi, Kenneth P. Nephew
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6504–6516.
https://doi.org/10.1158/1078-0432.CCR-14-1553
Published: 14 December 2014
View article titled, The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Open the PDF for The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer in another window
Includes: Supplementary data
Journal Articles

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert M. Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (23): 5918–5926.
https://doi.org/10.1158/1078-0432.CCR-14-1143
Published: 30 November 2014
View article titled, An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
Open the PDF for An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

Abstract IA17: Targeting the methylome for epigenetic resensitization of ovarian cancer

Kenneth P. Nephew, Daniela Matei, Pietro Taverna, Fang Fang, Jessica Tang, Gavin Choy, John Lyons, Mohammad Azab, Jay Pilrose, John Turchi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): IA17.
https://doi.org/10.1158/1078-0432.OVCA13-IA17
Published: 13 May 2014
View article titled, Abstract IA17: Targeting the methylome for epigenetic resensitization of ovarian cancer
Journal Articles

Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation

Daniela Matei, David D. Chang, Meei-Huey Jeng
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 681–690.
https://doi.org/10.1158/1078-0432.CCR-0754-03
Published: 03 February 2004
View article titled, Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation
Open the PDF for Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation in another window